Rare but Marvelous Efficacy of Neoadjuvant Chemotherapy for Adenocarcinoma of Rectum: A Case Report

Zongxian Zhao, Yuan Yao, Miao Jing Fan and Fusheng Wang

Fuyang People's Hospital, China

^*Correspondance to: Fusheng Wang 

 PDF  Full Text Case Report | Open Access

Abstract:

Background: The Neoadjuvant Chemotherapy (NACT) has been proved to reduce tumor early micro-metastatic focus, reduce tumor stage and increase probability of sparing sphincter, and even decrease risk of recurrence in Locally Advanced Rectal Cancer (LACR). Here, we reported a case of locally advanced rectal cancer that was rare extremely sensitive to NACT and reached pathological Complete Response (pCR) after only 3 courses of preoperative chemotherapy with CAPOX.
Case Report: A married 60-year-old male was diagnosed with locally advanced rectal cancer (cT3N2). He achieved pathological complete response after three courses of preoperative neoadjuvant chemotherapy with CAPOX. There were no clinically significant adverse reactions during entire chemotherapy period. Until now (February, 2022), the patient was still alive without
any signs or symptoms of tumor recurrence.
Conclusion: In conclusion, we documented an extremely rare case of LARC that developed pCR after only preoperative 3 courses of CAPOX. In addition, we provided a recommendation to employ early genetic detection to guide preoperative chemotherapy protocol. We should select appropriate NACT regimens according to different genotype of LARC and evaluate the effect of chemotherapy in time.

Keywords:

Locally advanced rectal cancer; Neoadjuvant chemotherapy; Pathological complete response; Genetic detection

Cite the Article:

Zhao Z, Yao Y, Fan MJ, Wang F. Rare but Marvelous Efficacy of Neoadjuvant Chemotherapy for Adenocarcinoma of Rectum: A Case Report. Clin Oncol. 2022;7:1912..